Morgan Stanley Maintains Overweight on Bath & Body Works, Lowers Price Target to $51
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley has maintained an Overweight rating on Bath & Body Works but has lowered the price target from $56 to $51.
September 05, 2024 | 11:05 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has kept its Overweight rating on Bath & Body Works, indicating continued confidence in the stock, but has reduced the price target from $56 to $51, suggesting a more cautious outlook.
The Overweight rating suggests that Morgan Stanley still sees potential in BBWI, but the lowered price target indicates a tempered expectation of growth or performance. This mixed signal may lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100